The Geroscience IndexWho's who in the science of aging
← All people
Nir Barzilai

Nir Barzilai

Professor of Medicine and Genetics; Ingeborg and Ira Leon Rennert Chair in Aging Research; Director, Institute for Geroscience · Albert Einstein College of Medicine

Bronx, NY, United States

ScientistAcademicDoctorCommunicator

Impact

Nir Barzilai is a physician-scientist at Albert Einstein College of Medicine whose work helped shape geroscience, the effort to target the biology of ageing itself rather than individual diseases. His studies of centenarians, largely in Ashkenazi Jewish families, supported the idea that people with exceptional longevity carry protective genes that delay ageing and age-related disease; early reports linked a distinctive lipoprotein phenotype and genotype to exceptional longevity (JAMA, 2003). His Einstein profile states that these findings informed CETP- and APOC3-targeted therapeutic approaches. He conceived the multicentre TAME (Targeting Aging with Metformin) trial, designed to establish biological ageing as a target for intervention, launched the AFAR SuperAgers Family Study, and is principal investigator of FAST, an AFAR-ARPA-H initiative to identify ageing biomarkers from existing clinical trials. He directs the Institute for Geroscience and the BIO-Vital Program, is President of the Global Academy for Health & Lifespan Research, sits on the AFAR Board (formerly its Scientific Director), and has received the NIA Nathan Shock Award and the IPSEN Longevity Award. He communicates widely to public audiences, including TEDx and TEDMED talks, the National Geographic documentary The Age of Aging, and his 2020 book Age Later.

Metrics

No public metrics available.

Research output

494 works · 42,142 citations · h-index 104 OpenAlex ↗

Selected publications

Research funding

50 NIH awards · USD 33M total NIH RePORTER ↗

  • Genetic variant-based drug discovery targeting conserved pathways of aging National Institute on Aging · 2023 · USD 3M
  • Genetic variant-based drug discovery targeting conserved pathways of aging National Institute on Aging · 2026 · USD 3M
  • Genetic variant-based drug discovery targeting conserved pathways of aging National Institute on Aging · 2024 · USD 3M
  • Genetic variant-based drug discovery targeting conserved pathways of aging National Institute on Aging · 2025 · USD 3M
  • Resilience to Alzheimer's disease in humans with exceptional longevity National Institute on Aging · 2021 · USD 1M

Links

Research fields

Associated labs

Sources & review · profile last updated 2026-09-29